Sort   by:  
 Page size 
UnknownHandScan criteria versus ACR/EULAR Boolean remission as treatment target in early rheumatoid arthritis: results of a randomized controlled trial.
Not available
S-EPMC12456276 | biostudies-literature
UnknownNovel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.
Not available
S-EPMC6471780 | biostudies-literature
UnknownMedication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count.
Not available
S-EPMC8566247 | biostudies-literature
UnknownEffectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
Not available
S-EPMC7449801 | biostudies-literature
UnknownPredictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.
Not available
S-EPMC6567570 | biostudies-literature
UnknownLow dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
Not available
S-EPMC9209692 | biostudies-literature
UnknownCoeliac disease in the Trondelag Health Study (HUNT), Norway, a population-based cohort of coeliac disease patients.
Not available
S-EPMC10806793 | biostudies-literature
UnknownEffect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Not available
S-EPMC8693274 | biostudies-literature
UnknownEffect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Not available
S-EPMC8097498 | biostudies-literature
UnknownEfficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
Not available
S-EPMC7519917 | biostudies-literature
Sort   by:  
 Page size